Last reviewed · How we verify
Loceryl NL 15 months
Amorolfine is a morpholine antifungal that inhibits fungal sterol synthesis by blocking both Δ14-reductase and Δ8-Δ7-isomerase enzymes in the ergosterol biosynthesis pathway.
Loceryl is an antifungal nail lacquer that inhibits fungal cell wall synthesis by disrupting ergosterol production. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | Loceryl NL 15 months |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Morpholine antifungal |
| Target | Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
By disrupting ergosterol production in fungal cell membranes, amorolfine compromises membrane integrity and function, leading to fungal cell death. This dual-enzyme inhibition makes it effective against a broad spectrum of dermatophytes, yeasts, and non-dermatophyte molds. The 15-month nail lacquer formulation provides sustained local delivery to treat onychomycosis (fungal nail infections).
Approved indications
- Onychomycosis (fungal nail infection) of toenails and fingernails
Common side effects
- Nail discoloration or discoloured nails
- Periungual erythema
- Local irritation at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loceryl NL 15 months CI brief — competitive landscape report
- Loceryl NL 15 months updates RSS · CI watch RSS
- Galderma R&D portfolio CI